Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Affimed to Present Data on AFM24 at AACR Annual Meeting 2018


Posted on: 15 Mar 18

Heidelberg, Germany, March 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company's AFM24 program at the AACR Annual Meeting 2018 in Chicago, IL.

Poster Presentation

Abstract:  Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors (#2786)

Session:  PO.IM02.11 - Therapeutic Antibodies, Including Engineered Antibodies 2

Date and Time:  Monday, April 16, 2018 1:00 PM - 5:00 PM (CT)

Location:  McCormick Place South, Exhibit Hall A, Poster Section 34/Board 19, Chicago, IL

Full abstract of the presentation can be accessed on the AACR website at www.aacr.org

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

Contact:

Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com, IR@affimed.com

GlobeNewswire
globenewswire.com

Last updated on: 15/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.